This review examines the role of membrane rafts in neural disease as a rationale for drug targeting utilizing lipid-based nanoparticles. The article begins with an overview of methodological issues involving the existence, sizes, and lifetimes of rafts, and then examines raft function in the etiologies of three major neural diseases—epilepsy, Parkinson’s disease, and Alzheimer’s disease—selected as promising candidates for raft-based therapeutics. Raft-targeting drug delivery systems involving liposomes and solid lipid nanoparticles are then examined in detail.
Bronswijk, P.; Cohen, A.F. The first recordings of pharmacological effects. Br. J. Clin. Pharmacol. 2008, 66, 588–593.
[3]
Rajendran, L.; Kn？lker, H.-J.; Simons, K. Subcellular targeting strategies for drug design and delivery. Nat. Rev. Drug Discov. 2010, 9, 29–42.
[4]
Breunig, M.; Bauer, S.; Goepferich, A. Polymers and nanoparticles: Intelligent tools for intracellular targeting? Eur. J. Pharm. Biopharm. 2008, 68, 112–128, doi:10.1016/j.ejpb.2007.06.010.
[5]
Sengupta, P.; Baird, B.; Holowka, D. Lipid rafts, fluid/fluid phase separation, and their relevance to plasma membrane structure and function. Semin. Cell Dev. Biol. 2007, 18, 583–590, doi:10.1016/j.semcdb.2007.07.010.
[6]
Pike, L. The challenge of lipid rafts. J. Lipid Res. 2009, 50, 323–328, doi:10.1194/jlr.R800040-JLR200.
[7]
Escribá, P.V. Membrane-lipid therapy: A new approach in molecular medicine. Trends Mol. Med. 2006, 12, 34–43, doi:10.1016/j.molmed.2005.11.004.
[8]
Michel, V.; Bakovic, M. Lipid rafts in health and disease. Biol. Cell 2007, 99, 129–140, doi:10.1042/BC20060051.
[9]
Sandhiya, S.; Dkhar, S.A.; Surendiran, A. Emerging trends of nanomedicine: An overview. Fundam. Clin. Pharmacol. 2009, 23, 263–269, doi:10.1111/j.1472-8206.2009.00692.x.
[10]
Juliano, R.L.; Alam, R.; Dixit, V.; Min Kang, H. Cell-targeting and cell-penetrating peptides for delivery of therapeutic and imaging agents. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2009, 1, 324–335, doi:10.1002/wnan.4.
Berta, A.I.; Boesze-Battaglia, K.; Magyar, A.; Szél, A.; Kiss, A.I. Localization of caveolin-1 and c-src in mature and differentiating photoreceptors: Raft proteins co-distribute with rhodopsin during development. J. Mol. Histol. 2011, 42, 523–533, doi:10.1007/s10735-011-9360-4.
[13]
Nu？ez, E.; Alonso-Torres, P.; Fornés, A.; Aragón, C.; López-Corcuera, B. The neuronal glycine transporter GLYT2 associates with membrane rafts: Functional modulation by lipid environment. J. Neurochem. 2008, 105, 2080–2090, doi:10.1111/j.1471-4159.2008.05292.x.
[14]
Cai, M.; Zhao, W.; Shang, X.; Jiang, J.; Ji, H.; Tang, Z.; Wang, H. Direct evidence of lipid rafts by in situ atomic force microscopy. Small 2012, 8, 1243–1250, doi:10.1002/smll.201102183.
[15]
Lai, E.C. Lipid rafts make for slippery platforms. J. Cell Biol. 2003, 162, 365–370, doi:10.1083/jcb.200307087.
[16]
Calder, P.C.; Yaqoob, P. Lipid rafts—Composition, characterization, and controversie. J. Nutr. 2007, 137, 545–547.
[17]
Fan, J.; Sammalkorpi, M.; Haataja, M. Formation and regulation of lipid microdomains in cell membranes: Theory, modeling, and speculation. FEBS Lett. 2009, 584, 1678–1684.
[18]
Brown, D.A.; Rose, J.K. Sorting of GPI-anchored proteins to glycolipid-enriched membrane subdomains during transport to the apical cell surface. Cell 1992, 68, 533–544, doi:10.1016/0092-8674(92)90189-J.
[19]
Pike, L.J. Lipid rafts: Bringing order to chaos. J. Lipid. Res. 2003, 44, 655–667, doi:10.1194/jlr.R200021-JLR200.
Day, C.A.; Kenworthy, A.K. Tracking microdomain dynamics in cell membranes. Biochim. Biophys. Acta 2009, 1788, 245–253, doi:10.1016/j.bbamem.2008.10.024.
[22]
Korade, Z.; Kenworthy, A.K. Lipid rafts, cholesterol, and the brain. Neuropharmacology 2008, 55, 1265–1273, doi:10.1016/j.neuropharm.2008.02.019.
[23]
Kenworthy, A.K.; Edidin, M. Distribution of a glycoslphosphatidylinositol-anchored protein at the apical surface of MDCK cells examined at a resolution of < 100 ？ using imaging fluorescence resonance energy transfer. J. Cell Biol. 1998, 142, 69–84, doi:10.1083/jcb.142.1.69.
[24]
Varma, R.; Mayor, S. GPI-anchored proteins are organized in submicron domains at the cell surface. Nature 1998, 394, 798–801.
[25]
Scheiffle, P.; Roth, M.G.; Simons, K. Interactions of influenza virus haemagglutinin with sphingolipid-cholesterol membrane domains via its transmembrane domain. EMBO J. 1997, 16, 5501–5508, doi:10.1093/emboj/16.18.5501.
[26]
Shvartsman, D.E.; Kotler, M.; Tall, R.D.; Roth, M.G.; Henis, Y.I. Differently anchored influenza hemagglutinin mutants display distinct interaction dynamics with mutual rafts. J. Cell Biol. 2003, 163, 879–888, doi:10.1083/jcb.200308142.
[27]
Niv, H.; Gutman, O.; Kloog, Y.; Henis, Y.I. Activated K-Ras and H-Ras display different interactions with saturable nonraft sites at the surface of live cells. J. Cell Biol. 2002, 157, 865–872.
[28]
Eisenberg, S.; Schvartsman, D.E.; Ehrlich, M.; Henis, Y.I. Clustering of raft-associated proteins in the external membrane leaflet modulates internal leaflet H-Ras diffusion and signaling. Mol. Cell. Biol. 2006, 19, 7190–7200.
[29]
Zhou, X.; Wang, L. Uses of single-particle tracking in living cells. Drug Discov. Ther. 2010, 4, 62–69.
[30]
Kusumi, A.; Nakada, C.; Ritchie, K.; Murase, K.; Suzuki, K.; Murakoshi, H.; Kasai, R.S.; Kondo, J.; Fujiwara, T. Paradigm shift of the plasma membrane concept from the two-dimensional continuum fluid to the partitioned fluid: High-speed single-molecule tracking of membrane molecules. Ann. Rev. Biophys. Biomol. Struct. 2005, 34, 351–378, doi:10.1146/annurev.biophys.34.040204.144637.
[31]
Tsuji, A.; Ohnishi, S. Restriction of the lateral motion of band 3 in the erythrocyte membrane by the cytoskeletal network: Dependence on spectrin association state. Biochemistry 1986, 25, 133–139.
[32]
Kusumi, A.; Koyama-Honda, I.; Suzuki, K. Molecular dynamics and interactions for creation of stimulation-induced stabilized rafts from small unstable steady-state rafts. Traffic 2004, 5, 213–230, doi:10.1111/j.1600-0854.2004.0178.x.
[33]
Anderson, R.G.W.; Jacobson, K. A role for lipid shells in targeting proteins to caveolae, rafts, and other lipid domain. Science 2002, 296, 1821–1824.
[34]
Fantini, J.; Barrantes, F.J. Sphingolipid/cholesterol regulation of neurotransmitter receptor conformation and function. Biochim. Biophys. Acta. 2009, 1788, 2345–2361.
[35]
Fantini, J.; Garmy, N.; Mahfoud, R.; Yahi, N. Lipid rafts: Structure, function, and role in HIV, Alzheimer’s, and prion diseases. Expert Rev. Mol. Med. 2002, 4, 1–22.
[36]
Simons, K.; Ehehalt, R. Cholesterol, lipid rafts, and diseases. J. Clin. Invest. 2002, 110, 597–603.
[37]
Escribá, P.V.; Gonzalez-Ros, J.M.; Gon？i, F.M.; Kinnunen, P.K.J.; Vigh, L.; Sánchez-Magraner, L.; Fernández, A.M.; Busquets, X.; Horváth, I.; Barceló-Coblijn, G. Membranes: A meeting point for lipids, proteins, and therapies. J. Cell. Mol. Med. 2008, 12, 829–875.
Wallace, R. Neural membrane signaling platforms. Int. J. Mol. Sci. 2010, 11, 2421–2442, doi:10.3390/ijms11062421.
[40]
Kwan, P.; Sander, J.W. The natural history of epilepsy: An epidemiological view. J. Neurol. Neurosurg. Psychiatry 2004, 75, 1376–1381, doi:10.1136/jnnp.2004.045690.
[41]
Kirsch, H.E.; Grossman, M. Tracing the roots and routes of cognitive dysfunction in epilepsy. Neurology 2008, 71, 1854–1855, doi:10.1212/01.wnl.0000333214.33299.fc.
Ngugi, A.K.; Kariuki, S.M.; Bottomley, C.; Kleinschmidt, I.; Sander, J.W.; Newton, C.R. Incidence of epilepsy: A systematic review and meta-analysis. Neurology 2011, 77, 1005–1012.
[44]
Rodin, E. The Prognosis of Patients with Epilepsy; Charles C. Thomas: Springfield, IL, USA, 1968.
[45]
Hering, H.; Lin, C.-C.; Sheng, M. Lipid rafts in the maintenance of synapses, dendritic spines, and surface AMPA receptor stability. J. Neurosci. 2003, 23, 3262–3271.
[46]
Schrattenholz, A.; Soskic, V. NMDA receptors are not alone: Dynamic regulation of NMDA receptor structure and function by neuregulins and transient cholesterol-rich membrane domains leads to disease-specific nuances of glutamate-signaling. Curr. Top. Med. Chem. 2006, 6, 663–686, doi:10.2174/156802606776894519.
Bowie, D. Ionotropic glutamate receptors & CNS disorders. CNS Neurol. Disord. Drug Targets 2008, 7, 129–143, doi:10.2174/187152708784083821.
[49]
Kalia, L.V.; Kalia, S.K.; Salter, M.W. NMDA receptors in clinical neurology: Excitatory times ahead. Lancet Neurol. 2008, 7, 742–755, doi:10.1016/S1474-4422(08)70165-0.
[50]
Lonze, B.E.; Ginty, D.D. Function and regulation of CREB family transcription factors in the nervous system. Neuron 2002, 35, 605–623, doi:10.1016/S0896-6273(02)00828-0.
[51]
McEachem, J.C.; Shaw, C.A. An alternative to the LTP orthodoxy: A plasticity-pathology continuum model. Brain Res. Rev. 1996, 1, 51–92.
[52]
McEachem, J.C.; Shaw, C.A. The plasticity-pathology continuum: Defining a role for the LTP phenomenon. J. Neurosci. Res. 1999, 58, 42–61, doi:10.1002/(SICI)1097-4547(19991001)58:1<42::AID-JNR6>3.0.CO;2-L.
[53]
Cooke, S.F.; Bliss, T.V.P. Plasticity in the human nervous system. Brain 2006, 129, 1659–1673.
[54]
Meador, K.J. The basic science of memory as it applies to epilepsy. Epilepsia 2007, 48, 23–25, doi:10.1111/j.1528-1167.2007.01396.x.
[55]
Naegele, J. Epilepsy and the plastic mind. Epilepsy Curr. 2009, 9, 166–169, doi:10.1111/j.1535-7511.2009.01331.x.
[56]
Ghasemi, M.; Schachter, S.C. The NMDA receptor complex as a therapeutic target in epilepsy: A review. Epilepsy Behav. 2011, 22, 617–640, doi:10.1016/j.yebeh.2011.07.024.
[57]
Zhang, Y.; Su, P.; Liang, P.; Liu, T.; Liu, X.; Liu, X.-Y.; Zhang, B.; Han, T.; Zhu, Y.-B.; Yin, D.-M.; Li, J.; Zhou, Z.; Wang, K.-W.; Wang, Y. The DREAM protein negatively regulates the NMDA receptor through interaction with the NR1 subunit. J. Neurosci. 2010, 30, 7575–7586.
[58]
Gomez-Villafuertes, R.; Torres, B.; Barrio, J.; Savignac, M.; Gabellini, N.; Rizzato, F.; Pintado, B.; Gutierrez-Adan, A.; Mellstr？m, B.; Carafoli, E.; Naranjo, J.R. Downstream regulatory element antagonist modulator regulates Ca2+ homeostasis and viability in cerebellar neurons. J. Neurosci. 2005, 25, 10822–10830.
[59]
Parkinson, J. An essay on the shaking palsy. J. Neuropsychiatry Clin. Neurosci. 2002, 14, 223–236, doi:10.1176/appi.neuropsych.14.2.223.
Morley, J.F.; Hurtig, H.J. Current understanding and management of Parkinson’s disease: Five new things. Neurology 2010, 75, S9–S15, doi:10.1212/WNL.0b013e3181fb3628.
[62]
Cookson, M.R.; Hardy, J.; Lewis, P.A. Genetic neuropathology of Parkinson’s Disease. Int. J. Clin. Exp. Pathol. 2008, 1, 217–231.
[63]
Cookson, M.R. Unraveling the role of defective genes. Prog. Brain Res. 2010, 183, 43–57, doi:10.1016/S0079-6123(10)83003-1.
[64]
Hardy, J. Genetic analysis of pathways to Parkinson disease. Neuron 2010, 68, 201–206, doi:10.1016/j.neuron.2010.10.014.
[65]
Cicchetti, F.; Drouin-Ouellet, J.; Gross, R.E. Environmental toxins and Parkinson’s disease: What have we learned from pesticide-induced animal models? Trends Pharmacol. Sci. 2009, 30, 475–483, doi:10.1016/j.tips.2009.06.005.
[66]
Satake, W.; Nakabayashi, Y.; Mizuta, I.; Hirota, Y.; Ito, C.; Kubo, M. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson’s disease. Nat. Genet. 2009, 41, 1303–1307, doi:10.1038/ng.485.
[67]
Simon-Sanchez, J.; Schulte, C.; Bras, J.M.; Sharma, M.; Gibbs, J.R.; Berg, D. Genome-wide association study reveals genetic risk underlying Parkinson’s disease. Nat. Genet. 2009, 41, 1308–1312, doi:10.1038/ng.487.
[68]
Goetz, C.G. The history of Parkinson’s disease: Early clinical descriptions and neurological therapies. Cold Spring Harb. Perspect. Med. 2011, 1, a008862.
[69]
Maguire-Zeiss, K.A. α-Synuclein: A therapeutic target for Parkinson’s disease. Pharmacol. Res. 2008, 58, 271–280, doi:10.1016/j.phrs.2008.09.006.
[70]
Auluck, P.K.; Caraveo, G.; Lindquist, S. α-Synuclein: Membrane interactions and toxicity in Parkinson’s disease. Ann. Rev. Cell Dev. Biol. 2010, 26, 211–233.
Scott, D.A.; Taberean, I.; Tang, Y.; Cartier, A.; Masliah, E.; Roy, S. A pathologic cascade leading to synaptic dysfunction in α-synuclein-induced neurodegeneration. J. Neurosci. 2010, 30, 8083–8095.
[76]
Sharma, M.; Barré, J.; Südhof, T.C. CSP α-promotes SNARE-complex assembly by chaperoning SNAP-25 during synaptic activity. Nat. Cell Biol. 2011, 13, 30–39, doi:10.1038/ncb2131.
[77]
Kubo, S.; Nemani, V.M.; Chalkey, R.J.; Anthony, M.D.; Hattori, N.; Mizuno, Y.; Edwards, R.H.; Fortin, D.L. A combinatorial code for the interaction of α-synuclein with membranes. J. Biol. Chem. 2005, 280, 31664–31672.
[78]
Outeiro, T.F.; Lindquist, S. Yeast cells provide insight into alpha-synuclein biology and pathobiology. Science 2003, 302, 1772–1775, doi:10.1126/science.1090439.
[79]
Bodner, C.R.; Dobson, C.M.; Bax, A. Multiple tight phospholipid-binding modes of alpha-synuclein revealed by solution NMR spectroscopy. J. Mol. Biol. 2009, 390, 775–790.
[80]
Devi, L.; Raghavendran, V.; Prabhu, B.M.; Avadhani, N.G.; Anandatheerthavarada, H.K. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J. Biol. Chem. 2008, 283, 9089–9100.
[81]
Esteves, A.R.; Arduino, D.M.; Silva, D.F.F.; Oliveira, C.R.; Cardoso, S.M. Mitochondrial dysfunction: The road to alpha-synuclein oligomerization in PD. Parkinson Dis. 2011, 1–20.
[82]
Keane, P.C.; Kurzawa, M.; Blain, P.G.; Morris, C.M. Mitochondrial dysfunction in Parkinson’s disease. Parkinson Dis. 2011, 2011, 1–18.
[83]
Fortin, D.L.; Troyer, M.D.; Nakamura, K.; Kubo, S.; Anthony, M.D.; Edwards, R.H. Lipid rafts mediate the synaptic localization of α-synuclein. J. Neurosci. 2004, 24, 6715–6723, doi:10.1523/JNEUROSCI.1594-04.2004.
[84]
Dawkins, R. The Blind Watchmaker: Why the Evidence of Evolution Reveals a Universe without Design; W.W. Norton: New York, NY, USA, 1986.
[85]
Abe, K.; Kobayashi, N.; Sode, K.; Ikebukuro, K. Peptide ligand screening of α-synuclein aggregation modulators by in silico panning. BMC Bioinforma. 2007, 8, 1–7, doi:10.1186/1471-2105-8-1.
[86]
El-Agnaf, O.; Paleologol, K.E.; Greer, B.; Abogrein, A.M.; King, J.E.; Salem, S.A.; Fullwood, N.G.; Benson, F.E.; Hewitt, R.; Ford, K.J.; Martin, F.L.; Harriott, P.; Cookson, M.R.; Allsop, D. A strategy for designing inhibitors of α-synuclein aggregation and toxicity as a novel treatment for Parkinson’s disease and related disorders. FASEB J. 2004, 18, 1315–1317.
[87]
M？ller, H.J.; Graeber, M.B. The case described by Alois Alzheimer in 1911. Historical and conceptual perspectives based on the clinical record and neurohistological sections. Eur. Arch. Psychiatry 1998, 248, 111–122.
Zheng, H.; Jiang, M.; Trumbauer, M.E.; Sirinathsinghji, D.J.S.; Hopkins, R.; Smith, D.W.; Heavens, R.P.; Dawson, G.R.; Boyce, S.; Conner, M.W.; Stevens, K.A.; Slunt, H.H.; Sisodia, S.S.; Chen, H.Y.; van der Ploeg, L.H.T. β-amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity. Cell 1995, 81, 525–531.
[91]
Cole, S.T.; Vassar, R. The role of amyloid precursor protein processing by BACE1, the β secretase in Alzheimer’s disease pathophysiology. J. Biol. Chem. 2008, 283, 29621–29625.
[92]
Deuss, M.; Reiss, K.; Hartmann, D. Part-time alpha-secretases: The functional biology of ADAM 9, 10, and 17. Curr. Alzheimer Res. 2008, 5, 187–201, doi:10.2174/156720508783954686.
[93]
Harris, B.; Pereira, I.; Parkin, E. Targeting ADAM 10 to lipid rafts in neuroblastoma SH-SY5Y cells impairs amyloidogenic processing of the amyloid precursor protein. Brain Res. 2009, 1296, 203–215, doi:10.1016/j.brainres.2009.07.105.
[94]
Fahrenholz, F. Alpha secretase as a therapeutic target. Curr. Alzheimer Res. 2007, 4, 412–417, doi:10.2174/156720507781788837.
[95]
Skovronsky, D.M.; Lee, V.M.-Y.; Trojanowski, J.Q. Neurodegenerative diseases: New concepts of pathogenesis and their therapeutic implications. Ann. Rev. Pathol. 2006, 1, 151–170, doi:10.1146/annurev.pathol.1.110304.100113.
[96]
Selkoe, D.J. Alzheimer’s disease is a synaptic failure. Science 2002, 298, 789–791, doi:10.1126/science.1074069.
[97]
Hong, L.; Koelsch, G.; Lin, X.; Wu, S.; Terzyan, S.; Ghosh, A.K.; Zhang, X.C.; Tang, J. Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor. Science 2000, 290, 150–153.
[98]
Tomita, T. Secretase inhibitors and modulators of Alzheimer’s disease. Expert Rev. Neurother. 2009, 9, 661–679, doi:10.1586/ern.09.24.
[99]
Cheng, H.; Vetrivel, K.S.; Gong, P.; Meckler, X.; Parent, A.; Thinakaran, G. Mechanisms of disease: New therapeutic strategies for Alzheimer’s disease—Targeting APP processing in lipid rafts. Nat. Clin. Pract. Neurol. 2007, 3, 374–382.
[100]
Ehehalt, R.; Keller, P.; Haass, C.; Thiele, C.; Simons, K. Amyloidogenic processing of the Alzheimer’s β amyloid precursor protein depends on lipid rafts. J. Cell Biol. 2003, 160, 113–123, doi:10.1083/jcb.200207113.
[101]
Simons, M.; Keller, P.; de Strooper, B.; Bayreuther, K.; Dotti, C.G.; Simons, K. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc. Natl. Acad. Sci. USA 1998, 95, 6460–6464.
[102]
Lakshmana, M.K.; Roy, S.; Mi, K.; Kang, D.E. Amyloidogenic processing of APP in lipid rafts. Open Biol. J. 2010, 3, 21–31, doi:10.2174/1874196701003020021.
[103]
Strittmatter, W.J.; Weisgraber, K.H.; Huang, D.Y.; Dong, L.M.; Salvesen, G.S.; Pericak-Vance, M.; Schmechel, D.; Saunders, A.M.; Goldgaber, D.; Roses, A.D. Binding of human apolipoprotein E to synthetic amyloid β-peptide: Isoform-specific effects and implications for late-onset Alzheimer’s disease. Proc. Natl. Acad. Sci. USA 1993, 90, 8098–8102.
[104]
Querfurth, H.W.; LaFerla, F.M. Mechanisms of disease: Alzheimer’s disease. N. Engl. J. Med. 2010, 362, 329–344, doi:10.1056/NEJMra0909142.
[105]
Fassbender, K.; Simons, M.; Bergmann, C.; Stroick, M.; Lutjohann, D.; Keller, P.; Runz, H.; Kuhl, S.; Bertsch, T.; von Bergmann, K.; Hennerici, M.; Bayreuther, K.; Hartmann, T. Simvastatin strongly reduces levels of Alzheimer’s disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc. Natl. Acad. Sci. USA 2001, 98, 5856–5861.
[106]
Refolo, L.M.; Sambamurti, K.; Efthimiopoulos, S.; Pappolla, M.A.; Robakis, N.K. Evidence that secretase cleavage of cell surface amyloid precursor occurs after normal endocytic internalization. J. Neurosci. Res. 1995, 40, 694–706, doi:10.1002/jnr.490400515.
[107]
Harder, T.; Scheiffele, P.; Verkade, P.; Simons, K. Lipid domain structure of the plasma membrane revealed by patching of membrane components. J. Cell Biol. 1998, 141, 929–942, doi:10.1083/jcb.141.4.929.
[108]
Marquer, C.; Devauges, V.; Cossec, J.-C.; Liot, G.; Lécart, S.; Sadou, F.; Duyckaerts, C.; Lévêque-Fort, S.; Potier, M.C. Local cholesterol increase triggers amyloid precursorprotein-Bace1 clustering in lipid rafts and rapid endocytosis. FASEB J. 2011, 25, 1295–1305.
[109]
Cole, S.L.; Vassar, R. The role of amyloid precursor protein processing by BACE1, the β-secretase, in Alzheimer disease pathophysiology. J. Biol. Chem. 2008, 283, 29621–29625, doi:10.1074/jbc.R800015200.
[110]
Cataldo, A.M.; Petanceska, S.; Terio, N.B.; Peterhoff, C.M.; Durham, R.; Mercken, M.; Mehta, P.D.; Buxbaum, J.; Haroutunian, V.; Nixon, R.A. Abeta localization in abnormal endosomes: Association with earliest Abeta elevations in AD and Down syndrome. Neurobiol. Aging 2004, 25, 1263–1272.
[111]
Jiang, Y.; Mullaney, K.A.; Peterhoff, C.M.; Che, S.; Schmidt, S.D.; Boyer-Boiteau, A.; Ginsberg, S.D.; Cataldo, A.M.; Mathews, P.M.; Nixon, R.A. Alzheimer’s-related endosome dysfunction in Down syndrome is Abeta-independent but requires APP and is reversed by BACE-1 inhibition. Proc. Natl. Acad. Sci. USA 2010, 107, 1630–1635.
[112]
Savonenko, A.V.; Melnikova, T.; Laird, F.M.; Stewart, K.-A.; Price, D.L.; Wong, P.C. Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes in BACE1-null mice. Proc. Natl. Acad. Sci. USA 2008, 105, 5585–5590.
[113]
Sankaranarayanan, S.; Price, E.A.; Wu, G.; Crouthamel, M.C.; Shi, X.P.; Tugusheva, K.; Tyler, K.X.; Kahana, J.; Ellis, J.; Jin, L.; Steele, T.; Stachel, S.; Coburn, C.; Simon, A.J. In vivo beta-secretase 1 inhibition leads to brain Abeta lowering and increased alpha-secretase processing of amyloid precursor protein without effect on neuregulin-1. J. Pharmacol. Exp. Ther. 2008, 324, 3431–3433.
[114]
McConlogue, L.; Buttini, M.; Anderson, J.P.; Brigham, E.F.; Chen, K.S.; Freedman, S.B.; Games, D.; Johnson-Wood, K.; Lee, M.; Zeller, M.; Liu, W.; Motter, R.; Sinha, S. Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP transgenic mice. J. Biol. Chem. 2007, 282, 26326–26334.
[115]
Feynman, R.P. There’s plenty of room at the bottom: An invitation to enter a new field of physics. J. Microelectromec. Syst. 1992, 1, 60–66, doi:10.1109/84.128057.
[116]
Silva, G.A. Introduction to nanotechnology and its applications to medicine. Surg. Neurol. 2004, 61, 216–220, doi:10.1016/j.surneu.2003.09.036.
[117]
Sandhiya, S.; Dkhar, S.A.; Surendiran, A. Emerging trends of nanomedicine—An overview. Fundam. Clin. Pharmacol. 2009, 23, 263–269, doi:10.1111/j.1472-8206.2009.00692.x.
[118]
Silva, G.A. Neuroscience nanotechnology: Progress, opportunities and challenges. Nat. Rev. Neurosci. 2006, 7, 65–74, doi:10.1038/nrn1827.
[119]
Lee, N.; Hyeon, T. Designed synthesis of uniformly sized iron oxide nanoparticles for efficient magnetic resonance imaging contrast agents. Chem. Soc. Rev. 2012, 41, 2575–2589, doi:10.1039/c1cs15248c.
[120]
Lu, C.; Stewart, D.J.; Lee, J.J.; Ji, L.; Ramesh, R.; Jayachandran, G.; Nunez, M.I.; Wistuba, I.I.; Erasmus, J.J.; Hicks, M.E.; Grimm, E.A.; Reuben, J.M.; Baladandayuthapani, V.; Templeton, N.S.; McMannis, J.D.; Roth, J.A. Phase I clinical trial of systemically administered TUSC2 (FUS1)-nanoparticles mediating functional gene transfer in humans. PLoS One 2012, 7, e34833.
[121]
Rupp, R.; Rosenthal, S.L.; Stanberry, L.R. VivaGelTM (SPL7013 Gel): A candidate dendrimer-microbicide for the prevention of HIV and HSV infection. Int. J. Nanomed. 2007, 2, 561–566.
[122]
Morachis, J.M.; Mahmoud, E.A.; Almutairi, A. Physical and chemical strategies for therapeutic delivery by using polymeric nanoparticles. Pharmacol. Rev. 2012, 64, 505–519, doi:10.1124/pr.111.005363.
[123]
Barandeh, F.; Nguyen, P.-L.; Kumar, R.; Iacobucci, G.J.; Kuznicki, M.L.; Kosterman, A.; Bergey, E.J.; Prasad, P.N.; Gunawardena, S. Organically modified silica nanoparticles are biocompatible and can be targeted to neurons in vivo. PLoS One 2012, 2, 1–15.
[124]
Deamer, D.W. From “Banghasomes” to liposomes: A memoir of Alec Bangham, 1921-2010. FASEB J. 2010, 24, 1308–1310, doi:10.1096/fj.10-0503.
[125]
Torchilin, V.P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 2005, 4, 145–160, doi:10.1038/nrd1632.
[126]
Schnyder, A.; Huwyler, J. Drug transport to brain with targeted liposomes. NeuroRx 2005, 2, 99–107, doi:10.1602/neurorx.2.1.99.
[127]
Martins, S.; Sarmento, B.; Ferreira, D.C.; Souto, E.B. Lipid-based colloidal carriers for peptide and protein delivery—Liposomes versus lipid nanoparaticles. Int. J. Nanomed. 2007, 2, 595–607.
[128]
Micheli, M.R.; Bova, R.; Magini, A.; Polidoro, M.; Emiliani, C. Lipid-based nanocarriers for CNS-targeted drug delivery. Recent Pat. CNS Drug Discov. 2012, 1, 71–86.
[129]
Juliano, R.I.; Alam, R.; Dixit, V.; Kang, H.M. Cell-targeting and cell-penetrating peptides for delivery of therapeutic and imaging agents. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2009, 1, 324–335, doi:10.1002/wnan.4.
[130]
Zhang, Y.; Zhang, Y.F.; Bryant, J.; Charles, A.; Boado, R.J.; Pardridge, W.M. Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. Clin. Cancer Res. 2004, 1, 3667–3677.
[131]
Gunawan, R.C.; Auguste, D.T. Immunoliposomes that target endothelium in vitro are dependent on lipid raft formation. Mol. Pharm. 2010, 7, 1569–1575, doi:10.1021/mp9003095.
[132]
Blasi, P.; Giovagnoli, S.; Schoubben, A.; Ricci, M.; Rossi, C. Solid lipid nanoparticles for targeted brain drug delivery. Adv. Drug Deliv. Rev. 2007, 10, 454–477.
[133]
Uner, M.; Yener, G. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int. J. Nanomed. 2007, 2, 289–300.
[134]
Kaur, I.P.; Bhandari, R.; Bhandari, S.; Kakkar, V. Potential of solid lipid nanoparticles in brain targeting. J. Control. Release 2008, 127, 97–109, doi:10.1016/j.jconrel.2007.12.018.
[135]
Sinha, V.R.; Srivastava, S.; Goel, H.; Jindal, V. Solid lipid nanoparticles (SLN’S)—Trends and implications in drug targeting. Int. J. Adv. Pharm. Sci. 2010, 1, 212–238.
[136]
Jawahar, N.; Gowthamarajan, K.; Meyyanathan, S.N.; Sood, S. Brain delivery by solid lipid nanoparticles for CNS drugs. Int. J. Pharm. Res. Dev. 2011, 3, 206–216.
[137]
Eldem, T.; Speiser, P.; Hincal, A. Optimization of spray-dried and –congealed lipid micropellets and characterization of their surface morphology by scanning electron microscopy. Pharm. Res. 1991, 8, 47–54, doi:10.1023/A:1015874121860.
[138]
Puri, A.; Loomis, K.; Smith, B.; Lee, J.H.; Yavlovich, A.; Heldman, E.; Blumenthal, R. Lipid-based nanoparticles as pharmaceutical drug carriers: From concepts to clinic. Crit. Rev. Ther. Drug Carrier Syst. 2009, 26, 523–580, doi:10.1615/CritRevTherDrugCarrierSyst.v26.i6.10.
[139]
Jain, A.; Agarwal, A.; Majumder, S.; Lariya, N.; Khaya, A.; Agrawal, H.; Majumdar, S.; Agrawal, G.P. Mannosylated solid lipid nanoparticles as vectors for site-specific delivery of an anti-cancer drug. J. Control. Release 2010, 20, 359–367.
[140]
Blasi, P.; Giovagnoli, S.; Schoubben, A.; Ricci, M.; Rossi, C. Solid lipid nanoparticles for targeted brain drug delivery. Adv. Drug Deliv. Rev. 2007, 10, 454–477.
[141]
Kreuter, J.; Petrov, V.E.; Kharkevich, D.A.; Alyautdin, R.N. Influence of the type of surfactant on the analgesic effects induced by the peptide dalagin after its delivery across the blood-brain barrier using surfactant-coated nanoparticles. J. Control. Release 1997, 49, 81–87, doi:10.1016/S0168-3659(97)00061-8.
[142]
Alyautdin, R.N.; Petrov, V.E.; Langer, K.; Berthold, A.; Kharkevich, D.A.; Kreuter, J. Delivery of loperamide across the blood-brain barrier with polysorbate-80 coated polybutylcyanoacrylate nanoparticles. Pharm. Res. 1997, 14, 325–328, doi:10.1023/A:1012098005098.
[143]
Friese, A.; Seiller, E.; Quack, G.; Lorenz, B.; Kreuter, J. Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacrylate) nanoparticles as a parenteral controlled release system. Eur. J. Pharm. Biopharm. 2000, 49, 103–109, doi:10.1016/S0939-6411(99)00073-9.
[144]
Gulyaev, A.E.; Gelperina, S.E.; Skidan, I.N.; Antropov, A.S.; Kivman, G.Y.; Kreuter, J. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm. Res. 1999, 16, 1564–1569, doi:10.1023/A:1018983904537.
[145]
Wilson, B.; Samanta, M.K.; Santhi, K.; Perumal, K.; Kumar, S.; Paramakrishnan, N.; Suresh, B. Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(butylcyanoacrylate) nanoparticles. Eur. J. Pharm. Biopharm. 2008, 70, 75–84, doi:10.1016/j.ejpb.2008.03.009.
[146]
Toffano, G.; Mazzari, S.; Zanotti, A.; Bruni, A. Synergistic effect of phosphatidylserine with gamma-aminobutyric acid in antagonizing the isoniazid-induced convulsions in mice. Neurochem. Res. 1984, 9, 1065–1073, doi:10.1007/BF00964802.
[147]
Loeb, C.; Benassi, E.; Besio, G.; Maffini, M.; Tanganelli, P. Liposome-entrapped GABA modifies behavioral and electrographic changes of penicillin-induced epileptic activity. Neurology 1982, 32, 1234–1238.
[148]
Snodgrass, S.R. GABA and epilepsy: Their complex relationship and the evolution of our understanding. J. Child Neurol. 1992, 7, 77–86, doi:10.1177/088307389200700114.
[149]
Bennewitz, M.F.; Saltzman, M.W. Nanotechnology for the delivery of drugs to the brain for epilepsy. Neurotherapeutics 2009, 6, 323–336, doi:10.1016/j.nurt.2009.01.018.
[150]
Ogden, K.K.; Traynelis, S.F. New advances in NMDA receptor pharmacology. Trends Pharmacol. Sci. 2011, 32, 726–733, doi:10.1016/j.tips.2011.08.003.
[151]
Klassen, T.; Davis, C.; Goldman, A.; Burgess, D.; Chen, T.; Wheeler, D.; McPherson, J.; Bourquin, T.; Lewis, L.; Villasana, D.; Morgan, M.; Muzny, D.; Gibbs, R.; Noebels, J. Exome sequencing of ion channel genes reveals complex profiles confounding personal risk assessment in epilepsy. Cell 2011, 145, 1036–1048, doi:10.1016/j.cell.2011.05.025.
[152]
During, M.J.; Freese, A.; Deutsch, A.Y.; Kibat, P.G.; Sabel, B.A.; Langer, R.; Roth, R.H. Biochemical and behavioral recovery in a rodent model of Parkinson’s disease following stereotactic implantation of dopamine-containing liposomes. Exp. Neurol. 1992, 115, 193–199, doi:10.1016/0014-4886(92)90053-S.
[153]
Jain, N.K.; Rana, N.C.; Jain, S.K. Brain drug delivery system bearing dopamine hydrochloride for effective management of parkinsonism. Drug Dev. Ind. Pharm. 1998, 24, 671–675, doi:10.3109/03639049809082370.
[154]
Khare, P.; Jain, A.; Jain, N.K.; Soni, V.; Jain, S.K. Glutamate-conjugated liposomes of dopamine hydrochloride for effective management of Parkinsonism’s. PDA J. Pharm. Sci.Technol. 2009, 63, 372–379.
[155]
Zeevalk, G.D.; Razmpour, R.; Bernard, L.P. Glutathione and Parkinson’s disease: Is this the elephant in the room? Biomed. Pharmacother. 2008, 62, 236–249, doi:10.1016/j.biopha.2008.01.017.
[156]
Martin, H.L.; Teismann, P. Glutathione—A review on its role and significance in Parkinson’s disease. FASEB J. 2009, 23, 3263–3272, doi:10.1096/fj.08-125443.
[157]
Lecker, S.H.; Goldberg, A.L.; Mitch, W.E. Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. J. Am. Soc. Nephrol. 2006, 17, 1807–1819, doi:10.1681/ASN.2006010083.
[158]
Zeevalk, G.D.; Manzino, L.; Sonsalla, P.K.; Bernard, L.P. Characterization of intracellular elevation of glutathione (GSH) with glutathione monoethyl ester and GSH in brain and neuronal cultures: Relevance to Parkinson’s disease. Exp. Neurol. 2007, 203, 512–520, doi:10.1016/j.expneurol.2006.09.004.
[159]
Wade, L.A.; Brady, H.M. Cysteine and cystine transport at the blood-brain barrier. J. Neurochem. 1981, 37, 730–734.
[160]
Zeevalk, G.D.; Bernard, L.P.; Guilford, F.T. Liposomal-glutathione provides maintenance of intracellular glutathione and neuroprotection in mesencephalic neuronal cells. Neurochem. Res. 2010, 35, 1575–1587, doi:10.1007/s11064-010-0217-0.
[161]
Gardoni, F.; Ghiglieri, V.; Luca, M.; Calabresi, P. Assemblies of glutamate receptor subunits with post-synaptic density proteins and their alterations in Parkinson’s disease. Prog. Brain Res. 2010, 183, 169–182, doi:10.1016/S0079-6123(10)83009-2.
[162]
Suzuki, T.; Zhang, J.; Miyazawa, S.; Liu, Q.; Farzan, M.R.; Yao, W.D. Association of membrane rafts and postsynaptic density: Proteomics, biochemical, and ultrastructural analyses. J. Neurochem. 2011, 119, 64–77, doi:10.1111/j.1471-4159.2011.07404.x.
[163]
Puthenveedu, M.A.; Yudowski, G.A.; von Zastrow, M. Endocytosis of neurotransmitter receptors: Location matters. Cell 2007, 130, 988–989, doi:10.1016/j.cell.2007.09.006.
[164]
El-Agnaf, O.; Paleologol, K.E.; Greer, B.; Abogrein, A.M.; King, J.E.; Salem, S.A.; Fullwood, N.G.; Benson, F.E.; Hewitt, R.; Ford, K.J.; Martin, F.L.; Harriott, P.; Cookson, M.R.; Allsop, D. A strategy for designing inhibitors of α-synuclein aggregation and toxicity as a novel treatment for Parkinson’s disease and related disorders. FASEB J. 2004, 18, 1315–1317.
[165]
Ghosh, A.K.; Gemma, S.; Tang, J. β-Secretase as a therapeutic target for Alzheimer’s disease. Neurotherapeutics 2008, 5, 399–408, doi:10.1016/j.nurt.2008.05.007.
Mutlu, N.B.; De？im, Z.; Yilmaz, S.; E？siz, D.; Nacar, A. New perspective for the treatment of Alzheimer diseases: Liposomal rivastigmine formulations. Drug Dev. Ind. Pharm. 2011, 37, 775–789, doi:10.3109/03639045.2010.541262.
[168]
Phaconpai, W.; Wattanathorn, J.; Muchimapura, S.; Tong-un, T.; Preechagoon, D. Neuroprotective effect of quercetin encapsulated liposomes: A novel therapeutic strategy against Alzheimer’s disease. Am. J. Appl. Sci. 2010, 7, 480–485, doi:10.3844/ajassp.2010.480.485.
[169]
Mourtas, S.; Canovi, M.; Zona, C.; Aurilia, D.; Niarakis, A.; LaFerla, B.; Salmona, M.; Nicotra, F.; Gobbi, M.; Antimisiaris, S.G. Curcumin-decorated nanoliposomes with very high affinity for amyloid-β1-42 peptide. Biomaterials 2011, 32, 1635–1645.
[170]
Picone, P.; Bondi, M.L.; Montana, G.; Bruno, A.; Pitarresi, G.; Giammona, G.; Di Carlo, M. Ferulic acid inhibits oxidative stress and cell death induced by Ab oligomers: Improved delivery by solid lipid nanoparticles. Free Radic. Res. 2009, 43, 1133–1145, doi:10.1080/10715760903214454.
[171]
DeMattos, R.B.; Bales, K.R.; Cummins, D.J.; Dodart, J.C.; Paul, S.M.; Holtzman, D.M. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer’s disease. Proc. Natl. Acad. Sci. USA 2001, 98, 8850–8855.
[172]
Gobbi, M.; Re, F.; Canovi, M.; Beeg, M.; Gregori, M.; Sesana, S.; Sonnino, S.; Brogioli, D.; Musicanti, C.; Gasco, P.; Salmona, M.; Masserini, M.E. Lipid-based nanoparticles with high binding affinity for amyloid-beta1-42 peptide. Biomaterials 2010, 31, 6519–6529.
[173]
Muhs, A.; Hickman, D.T.; Pihlgren, M.; Chuard, N.; Giriens, V.; Meerschman, C.; van der Auwera, I.; van Leuven, F.; Sugawara, M.; Weingertner, M.C.; Bechinger, B.; Greferath, R.; Kolonko, N.; Nagel-Steger, L.; Riesner, D.; Brady, R.O.; Pfeifer, A.; Nicolau, C. Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice. Proc. Natl. Acad. Sci. USA 2007, 104, 9810–9815.
[174]
Skovronsky, D.M.; Lee, V.M.; Trojanowski, J.Q. Neurodegenerative diseases: New concepts of pathogenesis and their therapeutic implications. Annu. Rev. Pathol. 2006, 1, 151–170, doi:10.1146/annurev.pathol.1.110304.100113.
[175]
Fasman, G.D.; Perczel, A.; Moore, C.D. Solubilization of beta-amyloid-(1-42)-peptide: Reversing the beta-sheet conformation induced by aluminum with silicates. Proc. Natl. Acad. Sci. USA 1995, 92, 369–371, doi:10.1073/pnas.92.2.369.
Kojro, E.; Gimpi, G.; Lammich, S.; Marz, W.; Fahrenholz, F. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha-secretase ADAM 10. Proc. Natl. Acad. Sci. USA 2001, 98, 5815–5820.
[178]
Cossec, J.C.; Simon, A.; Marquer, C.; Moldrich, R.X.; Leterrier, C.; Rossier, J.; Duyckaerts, C.; Lenkei, Z.; Poitier, M.C. Clathrin-dependent APP endocytosis and Abeta secretion are highly sensitive to the level of plasma membrane cholesterol. Biochim. Biophys. Acta 2010, 1801, 846–852, doi:10.1016/j.bbalip.2010.05.010.
[179]
Rajendran, L.; Schneider, A.; Schlechtingen, G.; Weidlich, S.; Ries, J.; Braxmeier, T.; Schwille, P.; Schulz, J.B.; Schroeder, C.; Simons, M.; Jennings, G.; Kn？lker, H.J.; Simons, K. Efficient inhibition of the Alzheimer’s disease beta-secretase by membrane targeting. Science 2008, 320, 520–523.
